top of page

ATRT Investigators -


Ashley Margol, MD, MS

Children’s Hospital Los Angeles [Los Angeles, CA]

Dr. Margol is currently an attending pediatric neuro-oncologist, Director of the Brain Tumor Center, Director of the Neuro-Oncology Program and Director of the Neuro-Oncology Fellowship Program at

Children’s Hospital Los Angeles and Associate Professor of Clinical Pediatrics at the Keck School of Medicine.

Her clinical research interests are focused on infant embryonal central nervous system tumors. She co-leads the Atypical Teratoid Rhabdoid Tumor (ATRT) Working Group for the Pacific Pediatric Neuro-Oncology Consortium (PNOC) and is working to develop a comprehensive registry to establish an external control cohort for patients with this rare tumor. She and others in the ATRT PNOC Working Group are currently developing an innovative and adaptive clinical trial for children with relapsed disease.

Investigator of Clinical Trial:  MV-NIS (NCT02962167)


Sabine Mueller, MD, PhD

UCSF Helen Diller Family Comprehensive Cancer Center [San Francisco, CA]

I am a board-certified neurologist and a pediatric neuro-oncologist with a research program focused on novel therapies for pediatric brain tumors and also on late effects in survivors of childhood brain tumors. I have received dedicated training in clinical research methodology through the Master's of Clinical Research Program at UCSF, which I completed in June 2015. I have significant experience conducting multi-center trials through established consortia, such as the Children's Oncology Group and the Pacific Pediatric Neuro-Oncology Consortium (PNOC), which I am co-leading. I also collaborate with the Childhood Cancer Survivor Study for my late effect research.  

Within PNOC, we are currently testing the feasibility of using a modified measles  virus for treatment of ATRT. Further, within PNOC we assembled leading experts in the field of ATRT research to develop the next, international ATRT clinical trial. The aim is to bring basic research scientists together with translational and clinical researches to develop a flexible clinical trial design that can quickly integrate new research findings.  VISIT PNOC SITE

PI of Clinical Trials:  


Alyssa Reddy, MD

UCSF Benioff Children's Hospital [San Francisco, CA]

Dr. Alyssa Reddy is a pediatric neurologist and neuro-oncologist with expertise in treating children who have tumors of the central nervous system. She has more than 25 years of experience in diagnosing and managing pediatric nervous system tumors.  Dr. Reddy aims to provide patients with compassionate care as well as access to cutting-edge treatment. Her research has focused on improving long-term survival and quality of life for children with brain tumors. She believes these goals are best accomplished through a collaborative approach from a diverse team of scientists and health care providers with the ability to offer new therapies through clinical trials.

Dr. Reddy led the first prospective cooperative group clinical trial specifically designed to treat ATRT. The study, Children’s Oncology Group, ACNS0333, demonstrated improved survival for patients with ATRT treated with intensive chemotherapy and focal radiation. Although outcomes have improved for children with ATRT, much work remains to be done to improve outcomes for all patients.

Dr. Reddy is co-chair of the PNOC ATRT Working Group and ATRT Registry Study.

Investigator of Clinical Trial:  Nivolumab-Ipilimumab (NCT04416568)


Sonia Partap, MD

Lucile Packard Children’s Hospital at Stanford [Palo Alto, CA]

I am a pediatric neuro-oncologist with research interests in Phase I and Phase II clinical trials for children and young adults with primary brain and spinal cord tumors. I am also site investigator for Stanford Children's many neuro-oncology trials. Our institution is actively involved in the Pediatric Brain Tumor Consortium (PBTC), Children's Brain Tumor Tissue Consortium (CBTTC), Children's Oncology Group (COG), and the Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC). As a part of these collaborations, we can be a part of the development of future therapies and bring options to our patients in hopes for a cure.

Investigator of Clinical Trial:  NCT0211422

Not Recruiting Patients


bottom of page